Brian Neel - Maravai Lifesciences Chief Production
| MRVI Stock | USD 5.81 0.23 4.12% |
Insider
Brian Neel is Chief Production of Maravai Lifesciences Holdings
| Age | 48 |
| Address | 10770 Wateridge Circle, San Diego, CA, United States, 92121 |
| Phone | 858 546 0004 |
| Web | https://www.maravai.com |
Maravai Lifesciences Management Efficiency
The company has return on total asset (ROA) of (0.0161) % which means that it has lost $0.0161 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4293) %, meaning that it created substantial loss on money invested by shareholders. Maravai Lifesciences' management efficiency ratios could be used to measure how well Maravai Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The Maravai Lifesciences' current Return On Tangible Assets is estimated to increase to -0.12. The Maravai Lifesciences' current Return On Capital Employed is estimated to increase to -0.02. As of now, Maravai Lifesciences' Intangibles To Total Assets are decreasing as compared to previous years. The Maravai Lifesciences' current Debt To Assets is estimated to increase to 0.46, while Total Assets are projected to decrease to under 1.5 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Richa Poddar | Agios Pharm | 42 | |
| Patrik Florencio | Amicus Therapeutics | N/A | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
| T Washburn | Agios Pharm | 42 | |
| Kari JD | Cytokinetics | N/A | |
| Timothy Rolph | Akero Therapeutics | 70 | |
| David Glynn | Krystal Biotech | N/A | |
| MBA MBA | Incyte | 64 | |
| Matthew Gline | Roivant Sciences | 40 | |
| Julia Butchko | Immunovant | 53 | |
| David Clark | Amicus Therapeutics | 48 | |
| Michelle Corral | Alector | N/A | |
| Steve MBBS | Halozyme Therapeutics | N/A | |
| Marc Harrison | Legend Biotech Corp | N/A | |
| Peter Heutink | Alector | N/A | |
| Rakhi Kumar | Roivant Sciences | 44 | |
| Bhaskar Chaudhuri | Arcutis Biotherapeutics | 69 | |
| FACC MD | Cytokinetics | 58 | |
| Vivek Ramaswamy | Roivant Sciences | 39 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0161 |
Maravai Lifesciences Leadership Team
Elected by the shareholders, the Maravai Lifesciences' board of directors comprises two types of representatives: Maravai Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Maravai. The board's role is to monitor Maravai Lifesciences' management team and ensure that shareholders' interests are well served. Maravai Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Maravai Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kurt Oreshack, General VP | ||
| Christine Dolan, Executive Technologies | ||
| Brian Neel, Chief Production | ||
| Peter Leddy, Executive Officer | ||
| Carl Hull, CoFounder Chairman | ||
| Christopher Benoit, Executive Enzymes | ||
| Becky Buzzeo, Executive Officer | ||
| Kate Broderick, Chief Officer | ||
| Andrew Burch, President Production | ||
| Rebecca Buzzeo, Executive Officer | ||
| Debra Hart, Director Relations | ||
| Doreen Pippen, VP Marketing | ||
| William III, Chief Officer | ||
| Kevin Herde, Executive CFO | ||
| Kevin CPA, Executive CFO | ||
| Kurt JD, General VP | ||
| Robert MBA, Chairman Board |
Maravai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Maravai Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0161 | ||||
| Profit Margin | (0.81) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 806.32 M | ||||
| Shares Outstanding | 141.84 M | ||||
| Shares Owned By Insiders | 1.35 % | ||||
| Shares Owned By Institutions | 98.65 % | ||||
| Number Of Shares Shorted | 7.9 M | ||||
| Price To Earning | 7.79 X |
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.